Landos Biopharma (NASDAQ:LABP) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Landos Biopharma (NASDAQ:LABPGet Rating) issued its earnings results on Thursday. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02), MarketWatch Earnings reports.

Shares of LABP traded up $0.01 during trading hours on Friday, hitting $0.68. The stock had a trading volume of 195,826 shares, compared to its average volume of 120,036. Landos Biopharma has a 12-month low of $0.61 and a 12-month high of $16.17. The company’s fifty day simple moving average is $1.29 and its 200 day simple moving average is $4.19.

A number of research firms have recently commented on LABP. Zacks Investment Research raised shares of Landos Biopharma from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research note on Wednesday, April 6th. Jefferies Financial Group lowered shares of Landos Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. Finally, Raymond James cut their target price on shares of Landos Biopharma from $24.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, March 25th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Landos Biopharma currently has an average rating of “Buy” and a consensus target price of $21.75.

Hedge funds and other institutional investors have recently modified their holdings of the company. Morgan Stanley grew its position in shares of Landos Biopharma by 1,337.0% during the second quarter. Morgan Stanley now owns 6,912 shares of the company’s stock worth $81,000 after buying an additional 6,431 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Landos Biopharma by 382.6% in the second quarter. Wells Fargo & Company MN now owns 9,526 shares of the company’s stock worth $110,000 after purchasing an additional 7,552 shares during the period. Goldman Sachs Group Inc. bought a new position in Landos Biopharma during the 4th quarter valued at $84,000. Bank of America Corp DE raised its holdings in shares of Landos Biopharma by 2,001.3% in the 4th quarter. Bank of America Corp DE now owns 31,225 shares of the company’s stock worth $150,000 after purchasing an additional 29,739 shares in the last quarter. Finally, Walleye Trading LLC purchased a new stake in shares of Landos Biopharma during the fourth quarter valued at $208,000. 66.53% of the stock is owned by institutional investors.

Landos Biopharma Company Profile (Get Rating)

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA).

See Also

Earnings History for Landos Biopharma (NASDAQ:LABP)

Receive News & Ratings for Landos Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landos Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.